Intellia partners with Regeneron, files for IPO

Intellia Therapeutics Inc. (Cambridge, Mass.) filed for an IPO and granted Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) exclusive rights to use its CRISPR- Cas9 ( CRISPR-associated protein 9) technology against up to 10 targets, primarily in the liver, to treat diseases including transthyretin (TTR)-mediated amyloidosis (ATTR).

Intellia filed to raise up to $120 million in a NASDAQ listing underwritten by Credit Suisse, Jefferies, Leerink and Wedbush PacGrow. Regeneron is to invest $50 million in a concurrent private placement at the IPO price. Intellia would be the second gene editing company to go public, following the February offering by Editas Medicine Inc. (NASDAQ:EDIT). ...